Gain Therapeutics (GANX) Retained Earnings (2020 - 2025)
Historic Retained Earnings for Gain Therapeutics (GANX) over the last 6 years, with Q3 2025 value amounting to -$81.2 million.
- Gain Therapeutics' Retained Earnings fell 3358.0% to -$81.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$81.2 million, marking a year-over-year decrease of 3358.0%. This contributed to the annual value of -$60.8 million for FY2024, which is 5781.34% down from last year.
- Per Gain Therapeutics' latest filing, its Retained Earnings stood at -$81.2 million for Q3 2025, which was down 3358.0% from -$81.2 million recorded in Q2 2025.
- In the past 5 years, Gain Therapeutics' Retained Earnings ranged from a high of $134323.0 in Q2 2023 and a low of -$81.2 million during Q1 2025
- Moreover, its 5-year median value for Retained Earnings was -$20.9 million (2022), whereas its average is -$35.5 million.
- Its Retained Earnings has fluctuated over the past 5 years, first soared by 10064.19% in 2023, then crashed by 6714579.42% in 2024.
- Gain Therapeutics' Retained Earnings (Quarter) stood at -$7.0 million in 2021, then crashed by 197.45% to -$20.9 million in 2022, then tumbled by 84.06% to -$38.5 million in 2023, then tumbled by 57.81% to -$60.8 million in 2024, then crashed by 33.58% to -$81.2 million in 2025.
- Its Retained Earnings was -$81.2 million in Q3 2025, compared to -$81.2 million in Q2 2025 and -$81.2 million in Q1 2025.